Date(s) - 22/10/2018
10:00 am - 11:30 am
The United Kingdom submitted its’ notification on 29 March 2017 to withdraw from the European Union. This means that unless a withdrawal agreement establishes another date, all EU primary and secondary Laws cease to apply to the UK from 30 March 2019 going forward.
Upon completion of this course, attendees will be able to accurately determine how Brexit will affect their operations and existing licensed Life Science Products in the UK and EU
It will allow companies to make plans on becoming compliant on “What is Known” and to remain agile as the rest of the implications become clearer
Areas Covered in the Session:
EU Regulatory and Legislative Structure [with and without the UK]
Issued Laws: Directives vs. Regulations
Impact on Filing Registrations with EMA in Q1 2019
Brexit Impact on License Holders Established in the UK
What if my EU Authorized Representative is Located in the UK?
What if the QPPV Resides in the UK?
What if API Manufacturing is Located in the UK?
Who Will Benefit:
Executive & General Management
Robert J. Russell For the past 9 years, He has been President of RJR Consulting, Inc. The company assists the pharmaceutical, medical device and biotech industries in understanding and complying with International Regulations affecting compliance, new product development, manufacturing and quality assurance.
Event Fee: One Dial-in One Attendee Price: US$150.00
Compliance4All DBA NetZealous,